We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+2.14%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.84B
AUM Growth
-$480M
(-21%)
Cap. Flow
-$470M
Cap. Flow
% of AUM
-25.56%
Top 10 Holdings %
Top 10 Hldgs %
46.94%
Holding
98
New
25
Increased
8
Reduced
28
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$106M |
| 2 |
Danaher
DHR
|
+$46.8M |
| 3 |
Johnson & Johnson
JNJ
|
+$44.6M |
| 4 |
Elevance Health
ELV
|
+$42.7M |
| 5 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$33.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$104M |
| 2 |
McKesson
MCK
|
+$83.1M |
| 3 |
Welltower
WELL
|
+$50.9M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$48.6M |
| 5 |
Petco
WOOF
|
+$48.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.78% |
| 2 | Consumer Discretionary | 2.94% |
| 3 | Financials | 1.26% |
| 4 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Humana
HUM
$44.1B
| $25.3M | 1.38% |
+54,640
| New | +$24.2M |
|
27
Syndax Pharmaceuticals
SNDX
$1.76B
| $25.3M | 1.38% |
1,157,560
-57,110
| -5% | -$1.06M |
|
|
RVNC
28
DELISTED
Revance Therapeutics, Inc.
RVNC
| $23.7M | 1.29% |
1,449,835
+1,368,335
| +1,679% | +$22.8M |
|
29
HCA Healthcare
HCA
$88.5B
| $21.7M | 1.18% |
84,270
-153,090
| -64% | -$37.5M |
|
|
LGV
30
DELISTED
Longview Acquisition Corp. II
LGV
| $21M | 1.14% |
2,135,900
| – | – |
|
31
Pfizer
PFE
$149B
| $20M | 1.09% |
+339,110
| New | +$16.8M |
|
32
Avantor
AVTR
$8.91B
| $18.1M | 0.98% |
+428,380
| New | +$16.9M |
|
33
Regeneron Pharmaceuticals
REGN
$79.5B
| $17.9M | 0.97% |
+28,320
| New | +$17.4M |
|
34
AbbVie
ABBV
$431B
| $16.9M | 0.92% |
+125,150
| New | +$14.8M |
|
|
35
McKesson
MCK
$102B
| $15.9M | 0.87% |
64,070
-378,400
| -86% | -$83.1M |
|
36
UnitedHealth
UNH
$367B
| $14.6M | 0.79% |
+29,000
| New | +$13.1M |
|
|
CANO
37
DELISTED
Cano Health, Inc.
CANO
| $14.1M | 0.77% |
15,867
-11,680
| -42% | -$12.3M |
|
38
BioMarin Pharmaceuticals
BMRN
$11.9B
| $14.1M | 0.77% |
+159,320
| New | +$13.1M |
|
39
Amgen
AMGN
$219B
| $14.1M | 0.77% |
+62,490
| New | +$13.2M |
|
|
RACB
40
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $12.9M | 0.7% |
1,324,800
| – | – |
|
41
Henry Schein
HSIC
$9.83B
| $9.89M | 0.54% |
+127,610
| New | +$9.75M |
|
|
IMGN
42
DELISTED
Immunogen Inc
IMGN
| $9.72M | 0.53% |
1,310,340
+1,110,340
| +555% | +$6.9M |
|
|
AFMD
43
DELISTED
Affimed
AFMD
| $9.51M | 0.52% |
172,193
-83,398
| -33% | -$5.15M |
|
|
CCXI
44
DELISTED
ChemoCentryx, Inc.
CCXI
| $8.76M | 0.48% |
+240,530
| New | +$8.44M |
|
45
Incyte
INCY
$24B
| $7.93M | 0.43% |
108,050
+33,050
| +44% | +$2.23M |
|
|
RAPT
46
DELISTED
RAPT Therapeutics
RAPT
| $6.66M | 0.36% |
22,675
-413
| -2% | -$110K |
|
47
Quanterix
QTRX
$180M
| $5.7M | 0.31% |
+134,340
| New | +$6.27M |
|
|
SGEN
48
DELISTED
Seagen Inc. Common Stock
SGEN
| $5.24M | 0.29% |
+33,890
| New | +$5.67M |
|
49
Hyperfine
HYPR
$97.5M
| $5.01M | 0.27% |
+691,650
| New | +$5.48M |
|
50
Veracyte
VCYT
$3.71B
| $4.93M | 0.27% |
119,710
+70,070
| +141% | +$3.1M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2021 Portfolio in Review
As of Q4 2021, HealthCor Management held 98 positions worth $1.84B, down 21% from $2.32B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
HealthCor Management withdrew a net $470M in Q4 2021, closing 30 positions and reducing 28 holdings. Its most notable exit was Welltower, an estimated $50.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 89% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, HealthCor Management opened a new position in Danaher worth $49.5M.
- HealthCor Management's largest Q4 2021 buy was Danaher: 169,866 shares worth $49.5M.
- HealthCor Management added most to Medtronic in Q4 2021, an estimated $106M increase.
- HealthCor Management's biggest Q4 2021 reduction was Bristol-Myers Squibb, cutting an estimated $104M.
- HealthCor Management fully exited Welltower in Q4 2021, selling an estimated $50.9M.
- HealthCor Management's ten largest holdings make up 47% of its $1.84B portfolio in Q4 2021.
- HealthCor Management opened 25 new positions and closed 30 in Q4 2021.
- HealthCor Management's portfolio value fell 21% quarter-over-quarter to $1.84B.
Based on HealthCor Management's 13F filing for Q4 2021, filed 14 Feb 2022.